214 related articles for article (PubMed ID: 11205153)
1. Immunopathogenic and clinical relevance of antibodies against myelin oligodendrocyte glycoprotein (MOG) in Multiple Sclerosis.
Berger T; Reindl M
J Neural Transm Suppl; 2000; (60):351-60. PubMed ID: 11205153
[TBL] [Abstract][Full Text] [Related]
2. The myelin oligodendrocyte glycoprotein (MOG): a model for antibody-mediated demyelination in experimental autoimmune encephalomyelitis and multiple sclerosis.
Stefferl A; Brehm U; Linington C
J Neural Transm Suppl; 2000; (58):123-33. PubMed ID: 11128602
[TBL] [Abstract][Full Text] [Related]
3. Antibodies from inflamed central nervous system tissue recognize myelin oligodendrocyte glycoprotein.
O'Connor KC; Appel H; Bregoli L; Call ME; Catz I; Chan JA; Moore NH; Warren KG; Wong SJ; Hafler DA; Wucherpfennig KW
J Immunol; 2005 Aug; 175(3):1974-82. PubMed ID: 16034142
[TBL] [Abstract][Full Text] [Related]
4. Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosis.
Zhou D; Srivastava R; Nessler S; Grummel V; Sommer N; Brück W; Hartung HP; Stadelmann C; Hemmer B
Proc Natl Acad Sci U S A; 2006 Dec; 103(50):19057-62. PubMed ID: 17142321
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
Reindl M; Linington C; Brehm U; Egg R; Dilitz E; Deisenhammer F; Poewe W; Berger T
Brain; 1999 Nov; 122 ( Pt 11)():2047-56. PubMed ID: 10545390
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against glycosylated native MOG are elevated in patients with multiple sclerosis.
Lolli F; Rovero P; Chelli M; Papini AM
Neurology; 2005 Sep; 65(5):781-2; author reply 781-2. PubMed ID: 16157927
[No Abstract] [Full Text] [Related]
7. Immune responses against the myelin/oligodendrocyte glycoprotein in experimental autoimmune demyelination.
von Büdingen HC; Tanuma N; Villoslada P; Ouallet JC; Hauser SL; Genain CP
J Clin Immunol; 2001 May; 21(3):155-70. PubMed ID: 11403222
[TBL] [Abstract][Full Text] [Related]
8. Anti-MOG autoantibodies in Italian multiple sclerosis patients: specificity, sensitivity and clinical association.
Mantegazza R; Cristaldini P; Bernasconi P; Baggi F; Pedotti R; Piccini I; Mascoli N; La Mantia L; Antozzi C; Simoncini O; Cornelio F; Milanese C
Int Immunol; 2004 Apr; 16(4):559-65. PubMed ID: 15039386
[TBL] [Abstract][Full Text] [Related]
9. Signaling cascades activated upon antibody cross-linking of myelin oligodendrocyte glycoprotein: potential implications for multiple sclerosis.
Marta CB; Montano MB; Taylor CM; Taylor AL; Bansal R; Pfeiffer SE
J Biol Chem; 2005 Mar; 280(10):8985-93. PubMed ID: 15634682
[TBL] [Abstract][Full Text] [Related]
10. Commentary: Sorting the wheat from the chaff: identifying demyelinating components of the myelin oligodendrocyte glycoprotein (MOG)-specific autoantibody repertoire.
Mathey E; Breithaupt C; Schubart AS; Linington C
Eur J Immunol; 2004 Aug; 34(8):2065-71. PubMed ID: 15259003
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic myelin oligodendrocyte glycoprotein antibodies recognize glycosylated epitopes and perturb oligodendrocyte physiology.
Marta CB; Oliver AR; Sweet RA; Pfeiffer SE; Ruddle NH
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):13992-7. PubMed ID: 16172404
[TBL] [Abstract][Full Text] [Related]
12. Homogeneity of active demyelinating lesions in established multiple sclerosis.
Breij EC; Brink BP; Veerhuis R; van den Berg C; Vloet R; Yan R; Dijkstra CD; van der Valk P; Bö L
Ann Neurol; 2008 Jan; 63(1):16-25. PubMed ID: 18232012
[TBL] [Abstract][Full Text] [Related]
13. The role of myelin oligodendrocyte glycoprotein in autoimmune demyelination: a target for multiple sclerosis therapy?
Lee DH; Linker RA
Expert Opin Ther Targets; 2012 May; 16(5):451-62. PubMed ID: 22494461
[TBL] [Abstract][Full Text] [Related]
14. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein.
O'Connor KC; McLaughlin KA; De Jager PL; Chitnis T; Bettelli E; Xu C; Robinson WH; Cherry SV; Bar-Or A; Banwell B; Fukaura H; Fukazawa T; Tenembaum S; Wong SJ; Tavakoli NP; Idrissova Z; Viglietta V; Rostasy K; Pohl D; Dale RC; Freedman M; Steinman L; Buckle GJ; Kuchroo VK; Hafler DA; Wucherpfennig KW
Nat Med; 2007 Feb; 13(2):211-7. PubMed ID: 17237795
[TBL] [Abstract][Full Text] [Related]
15. Rhesus monkeys are highly susceptible to experimental autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein: characterisation of immunodominant T- and B-cell epitopes.
Kerlero de Rosbo N; Brok HP; Bauer J; Kaye JF; 't Hart BA; Ben-Nun A
J Neuroimmunol; 2000 Oct; 110(1-2):83-96. PubMed ID: 11024537
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG).
Brehm U; Piddlesden SJ; Gardinier MV; Linington C
J Neuroimmunol; 1999 Jun; 97(1-2):9-15. PubMed ID: 10408984
[TBL] [Abstract][Full Text] [Related]
17. Detection of brain-specific autoantibodies to myelin oligodendrocyte glycoprotein, S100beta and myelin basic protein in patients with Devic's neuromyelitis optica.
Haase CG; Schmidt S
Neurosci Lett; 2001 Jul; 307(2):131-3. PubMed ID: 11427318
[TBL] [Abstract][Full Text] [Related]
18. C3d binding to the myelin oligodendrocyte glycoprotein results in an exacerbated experimental autoimmune encephalomyelitis.
Jégou JF; Chan P; Schouft MT; Griffiths MR; Neal JW; Gasque P; Vaudry H; Fontaine M
J Immunol; 2007 Mar; 178(5):3323-31. PubMed ID: 17312184
[TBL] [Abstract][Full Text] [Related]
19. Myelin oligodendrocyte glycoprotein antibodies in pathologically proven multiple sclerosis: frequency, stability and clinicopathologic correlations.
Pittock SJ; Reindl M; Achenbach S; Berger T; Bruck W; Konig F; Morales Y; Lassmann H; Bryant S; Moore SB; Keegan BM; Lucchinetti CF
Mult Scler; 2007 Jan; 13(1):7-16. PubMed ID: 17294606
[TBL] [Abstract][Full Text] [Related]
20. Antibodies to native myelin oligodendrocyte glycoprotein are serologic markers of early inflammation in multiple sclerosis.
Lalive PH; Menge T; Delarasse C; Della Gaspera B; Pham-Dinh D; Villoslada P; von Büdingen HC; Genain CP
Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2280-5. PubMed ID: 16461459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
